Vaxfab Enterprises Closes Trading Window April 1 Ahead of FY26 Results

Vaxfab Enterprises Limited has announced that its trading window for designated persons will close starting April 1, 2026. This action complies with SEBI (Prohibition of Insider Trading) Regulations, 2015, and is taken as the company prepares to announce its audited financial results for the fiscal year ending March 31, 2026.

Filing Details

Vaxfab Enterprises Limited informed the BSE (Bombay Stock Exchange) that its trading window will close starting April 1, 2026. This temporary halt in trading for company insiders coincides with the company's fiscal year-end on March 31, 2026. The trading window is set to reopen 48 hours after the company officially declares its audited financial results for the fiscal year.

Purpose of the Closure

The closure is a standard compliance measure aimed at preventing potential insider trading. It ensures that all key financial information is released to the public at the same time, maintaining fair market practices. Following these SEBI regulations helps build and maintain investor confidence in the market.

Company Background and Context

Vaxfab Enterprises Limited, formerly known as Ellora Trading Limited, trades agricultural products and is expanding into textiles and garments. The company has a pattern of closing its trading window before financial result announcements to meet SEBI requirements. However, recent financial performance shows challenges, including a net loss of ₹3.24 crore in Q3 FY26. The company's stock has also seen volatility and shareholder dilution over the past year.

Who is Affected

This trading restriction applies to designated persons, which includes directors, promoters, and their immediate relatives. These individuals are prohibited from buying or selling Vaxfab shares until the company releases its audited FY26 financial results and for 48 hours afterward.

Potential Risks

The main risk involves potential insider trading if designated persons do not strictly adhere to the regulations. Investors will also be watching the upcoming audited FY26 results closely for any significant trends or concerns, particularly in light of recent quarterly losses and stock price fluctuations.

Key Financial Figures

For the third quarter of fiscal year 2026 (ending December 2025), Vaxfab reported a net loss of ₹3.24 crore. Revenue during Q3 FY26 was ₹15.66 crore, with an operating profit margin of 2.04%.

What Investors Should Watch

Investors will await the official announcement of Vaxfab Enterprises Limited's audited financial results for the fiscal year ended March 31, 2026. Updates from the company on its business diversification efforts or ongoing financial performance will also be key. The market's response to the FY26 results will be closely observed.